It has been shown that resistance develops within 9–14 months in most patients with EGFR-mutated NSCLC treated with first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib, and afatinib (Mok et al., 2009; Rosell et al., 2012; Tricker et al., 2015). This evidence concerns the gene EGFR and non-small cell lung carcinoma.